Both ADMA Biologics Inc. (NASDAQ:ADMA) and Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics Inc.	24.93M	5.15	60.69M	-1.42	0.00
Paratek Pharmaceuticals Inc.	5.17M	41.69	111.46M	-3.64	0.00

Table 1 shows the top-line revenue, earnings per share and valuation for ADMA Biologics Inc. and Paratek Pharmaceuticals Inc.

Profitability

Table 2 has ADMA Biologics Inc. and Paratek Pharmaceuticals Inc.’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
ADMA Biologics Inc.	-243.44%	-159.4%	-57.4%
Paratek Pharmaceuticals Inc.	-2,155.90%	-132.5%	-44.6%

Volatility and Risk

A 2.07 beta means ADMA Biologics Inc.’s volatility is 107.00% more than Standard & Poor’s 500’s volatility. Competitively, Paratek Pharmaceuticals Inc.’s beta is 1.03 which is 3.00% more volatile than Standard & Poor’s 500.

Liquidity

The Current Ratio of ADMA Biologics Inc. is 6.3 while its Quick Ratio stands at 4.9. The Current Ratio of rival Paratek Pharmaceuticals Inc. is 11.4 and its Quick Ratio is has 11.4. Paratek Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than ADMA Biologics Inc.

Analyst Ratings

Recommendations and Ratings for ADMA Biologics Inc. and Paratek Pharmaceuticals Inc. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
ADMA Biologics Inc.	0	0	2	3.00
Paratek Pharmaceuticals Inc.	0	1	1	2.50

ADMA Biologics Inc. has a 261.01% upside potential and a consensus target price of $10. On the other hand, Paratek Pharmaceuticals Inc.’s potential upside is 102.10% and its consensus target price is $13.5. The results from earlier shows that analysts opinion suggest that ADMA Biologics Inc. seems more appealing than Paratek Pharmaceuticals Inc.

Institutional & Insider Ownership

The shares of both ADMA Biologics Inc. and Paratek Pharmaceuticals Inc. are owned by institutional investors at 58.9% and 82.6% respectively. ADMA Biologics Inc.’s share owned by insiders are 0.5%. On the other hand, insiders owned about 2.9% of Paratek Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
ADMA Biologics Inc.	-15.56%	-22.74%	-31.33%	-4.09%	64.21%	38.63%
Paratek Pharmaceuticals Inc.	-9.11%	-11.05%	-31.2%	-36.88%	-61.02%	-61.56%

For the past year ADMA Biologics Inc. has 38.63% stronger performance while Paratek Pharmaceuticals Inc. has -61.56% weaker performance.

Summary

On 8 of the 12 factors ADMA Biologics Inc. beats Paratek Pharmaceuticals Inc.

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. ADMA Biologics, Inc. was founded in 2004 and is based in Ramsey, New Jersey.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.